Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined With Pembrolizumab or Cemiplimab

NCT03684785 is registered in ClinicalTrials.gov with Exicure, Inc. as lead sponsor.

NCT NCT03684785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03684785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined With Pembrolizumab or Cemiplimab
Lead sponsor
Exicure, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 13, 2018
Completion date
March 30, 2022
Enrollment
57 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic cutaneous squamous cell carcinoma, advanced or metastatic head and neck squamous cell carcinoma, advanced or metastatic melanoma, advanced or metastatic merkel cell carcinoma, advanced or metastatic solid tumors